Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review

Kocher, Serge; Müller, Wolfgang; Resch, Bernhard

doi:10.1016/j.ijantimicag.2010.03.030

Cited by 27 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The linezolid therapy was safe and effective in the neonatal period similar with the literature. 2,14 Several considerations should be noted when interpreting the results. Firstly, this was a retrospective study, which has inherent limitations when compared to randomized clinical trials.…”

Section: Discussionmentioning

confidence: 99%

“…1,2 It has an excellent activity against most methicillin-sensitive and methicillin-resistant Grampositive bacteria. 3 Linezolid was originally approved by Food and Drug Administration of United States for pediatric use in 2002, for treatment indicated infections, such as skin and skin structure infections, communityacquired and nosocomial pneumonia, and infections with vancomycinresistant Enterococcus faecium.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Linezolid-related adverse effects in clinical practice in children

et al. 2017

View full text Add to dashboard Cite

Introduction:Linezolid may cause adverse effects such as thrombocytopenia, which were found to be dependent on receiving linezolid for longer than 2 weeks. There are limited studies concerning the safety and timing of linezolidrelated adverse effects in children. Objective of this study was to evaluate the incidence of adverse effects associated with linezolid, with especially focusing on the time of occurrence. Population and Methods: All children (≤18 years of age) who received ≥3 days of linezolid therapy were included in this study. Adverse effects attributed to linezolid and time of occurrence of side effects was evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Linezolid-related adverse effects in clinical practice in children

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Grampositive bacteria include important pathogens, known to be a leading cause of infectious diseases. They represent the most common and troublesome causes of nosocomial infections in neonatal intensive care units (Kocher et al, 2010). The increasing occurrence of bacteria resistant to antibiotics represents a serious threat for the treatment of infectious diseases.…”

Section: Discussionmentioning

confidence: 99%

“…Also, Gram-positive pathogens are the most common and troublesome causes of nosocomial infections in neonatal intensive care units (Kocher et al, 2010). Owing to the increased incidence of infections caused by these pathogens, the development of novel agents with antibacterial activity is requisite.…”

Section: Introductionmentioning

confidence: 99%

Isolation and biological activity of compounds fromGarcinia preussii

Messi

Lannang

et al. 2014

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: Plants of the genus Garcinia (Clusiaceae) are traditionally used to relieve stomachaches, toothaches, and as a chew stick. Objective: In order to determine which compounds were responsible for these activities, a phytochemical investigation of the fruits and leaves of Garcinia preussii Engl. was pursued. Materials and methods: Plants were extracted by solvents of various polarities. Compounds isolation was then carried out using chromatography methods (medium-and high-pressure liquid chromatography, open column and thin-layer chromatography). The isolated compounds were identified and characterized by using 1D and 2D NMR spectroscopies. The antioxidant activity was evaluated using DPPH , ABTS À , ALP, and ORAC assays. The antimicrobial activity was assayed against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis by determining the minimum inhibitory concentration (MIC) value. The cytotoxic activity of most of the isolated compounds was evaluated on a small panel of human cancer cell lines (DU145, HeLa, HT-29, and A431) using the XTT method. Results: The phytochemical investigation of G. preussii led to the isolation of eight known compounds, six benzophenones and two flavonoids. These compounds were tested for their biological activities. 1, 2, 3, 4, 7 and 8 demonstrated a high free radical scavenging activity with ER 50 ranging from 0.1 to 0.7. The antimicrobial activity was shown only against Gram-positive bacteria for 1, 4, and 5. A moderate cytotoxic activity with IC 50 ranging from 7 to 50 mM was observed, except for 6 which was not active. Conclusion: These results appear to support some of the properties reported for Garcinia species.

show abstract

“…1,2 Tiene una actividad excelente contra la mayoría de las bacterias grampositivas sensibles a la meticilina y meticilino-resistentes. 3 Inicialmente, la linezolida fue aprobada en 2002 por la Administración de A l i m e n t o s y M e d i c a m e n t o s d e los Estados Unidos para su uso pediátrico, en el tratamiento de infecciones, como las cutáneas y de partes blandas, neumonías intra-y extrahopitalarias e infecciones por Enterococcus faecium resistente a la vancomicina.…”

Section: Introductionunclassified

Efectos adversos relacionados con la linezolida en la práctica clínica pediátrica

2017

Arch Argent Pediat

View full text Add to dashboard Cite

RESUMENIntroducción. La linezolida puede causar efectos adversos, como trombocitopenia, que, según lo observado, se relacionan con la administración de linezolida durante más de 2 semanas. Se ha realizado una cantidad limitada de estudios sobre la seguridad y el momento de aparición de los efectos adversos relacionados con la linezolida en los niños. El objetivo de este estudio fue evaluar la incidencia de los efectos adversos asociados con la linezolida, especialmente en relación con el momento de su aparición. Población y métodos. Se incluyeron a todos los niños (≤ 18 años de edad) que recibieron tratamiento con linezolida durante ≥ 3 días. Se evaluaron los efectos adversos atribuidos a la linezolida y el momento de aparición de los efectos secundarios. Resultados. En total, se incluyeron 179 niños. La mediana de edad de los pacientes fue 4 años (entre 6 días y 17 años). Durante el tratamiento con linezolida, 36 (20,1%) pacientes tuvieron efectos adversos. El efecto adverso más frecuente fue la trombocitopenia, detectada en 26 (14,5%) pacientes. Los demás efectos adversos fueron: elevación de las enzimas hepáticas en 4 pacientes, leucopenia y anemia en 2 pacientes, disfunción renal en 1 y reacciones cutáneas graves en 3 pacientes. Los efectos adversos se detectaron dentro de una mediana de 7,5 días de tratamiento (intervalo: de 4 a 18 días). Entre los 36 pacientes, 26 (72,2%) presentaron un efecto adverso en los primeros 10 días de tratamiento. Conclusiones. Se detectaron efectos adversos transitorios en el 20,1% de los pacientes durante el tratamiento con linezolida. Estos efectos adversos podrían detectarse antes de los 10 días de tratamiento. La linezolida debe recetarse de manera segura a los niños siempre que se vigilen los efectos adversos, en especial el recuento de trombocitos y el nivel de enzimas hepáticas. INTRODUCCIÓNL a l i n e z o l i d a e s e l p r i m e r a n t i b i ó t i c o d e l a c l a s e d e l a s oxazolidinonas aprobado y usado en niños, incluidos los recién nacidos prematuros.1,2 Tiene una actividad excelente contra la mayoría de las bacterias grampositivas sensibles a la meticilina y meticilino-resistentes. 3 Inicialmente, la linezolida fue aprobada en 2002 por la Administración de A l i m e n t o s y M e d i c a m e n t o s d e los Estados Unidos para su uso pediátrico, en el tratamiento de infecciones, como las cutáneas y de partes blandas, neumonías intra-y extrahopitalarias e infecciones por Enterococcus faecium resistente a la vancomicina. 4 En comparación con los antibióticos glucopéptidos, las ventajas de la linezolida son su eficacia clínica y microbiológica, la excelente penetración tisular y el hecho de que no es necesario determinar la concentración plasmática del fármaco.5 Su perfil de toxicidad es bajo frente a los antibióticos glucopéptidos. Sin embargo, se ha informado que la linezolida causa e f e c t o s a d v e r s o s g r a v e s , c o m o neuropatía, elevación de las enzimas hepáticas y mielosupresión, incluso trombocitopenia y leucopenia. 6L o s d a t o s s o b ...

show abstract

Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review

Cited by 27 publications

References 30 publications

Linezolid-related adverse effects in clinical practice in children

Linezolid-related adverse effects in clinical practice in children

Isolation and biological activity of compounds fromGarcinia preussii

Efectos adversos relacionados con la linezolida en la práctica clínica pediátrica

Contact Info

Product

Resources

About